RCT · 2022
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff AM, Aronne LJ, Ahmad NN, et al. · New England Journal of Medicine
2,539 participants; 20.9% mean weight reduction at 72 weeks on the 15 mg dose, approaching bariatric-surgery territory.
Key findings
- 57% of the 15 mg group lost ≥20% of body weight
- 95% of those with prediabetes reverted to normoglycemia
- Discontinuation from adverse events was 4.3–7.1%
Limitations
Predominantly female cohort; no cardiovascular outcome endpoint in this trial.